世界の非アルコール性脂肪性肝炎（NASH）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4158 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、非アルコール性脂肪性肝炎（NASH）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E）、用途別市場規模（病院薬局、オンラインプロバイダー、ドラッグストア）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・非アルコール性脂肪性肝炎（NASH）の市場動向 ・企業の競争状況、市場シェア ・非アルコール性脂肪性肝炎（NASH）の種類別市場規模（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E） ・非アルコール性脂肪性肝炎（NASH）の用途別市場規模（病院薬局、オンラインプロバイダー、ドラッグストア） ・非アルコール性脂肪性肝炎（NASH）の北米市場規模2016-2027（アメリカ、カナダ） ・非アルコール性脂肪性肝炎（NASH）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・非アルコール性脂肪性肝炎（NASH）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非アルコール性脂肪性肝炎（NASH）の中南米市場規模2016-2027（メキシコ、ブラジル） ・非アルコール性脂肪性肝炎（NASH）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Tobira Therapeutics、Cadila Healthcare、Conatus Pharmaceuticals、Galmed Pharmaceuticals、Gemphire Therapeutics、Genfit、Gilead Sciences、Intercept Pharmaceuticals、Novartis International、Takeda） ・結論

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

Market Analysis and Insights: Global Nonalcoholic Steatohepatitis (NASH) Market
The global Nonalcoholic Steatohepatitis (NASH) market size is projected to reach US$ 31510 million by 2026, from US$ 2086.6 million in 2019, at a CAGR of 46.7% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nonalcoholic Steatohepatitis (NASH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nonalcoholic Steatohepatitis (NASH) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nonalcoholic Steatohepatitis (NASH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nonalcoholic Steatohepatitis (NASH) market.

Global Nonalcoholic Steatohepatitis (NASH) Scope and Market Size
Nonalcoholic Steatohepatitis (NASH) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Steatohepatitis (NASH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Obeticholic acid（OCA）
Selonsertib
Emricasan
GR-MD-02
IMM-124E

Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Tobira Therapeutics
Cadila Healthcare
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Gemphire Therapeutics
Genfit
Gilead Sciences
Intercept Pharmaceuticals
Novartis International

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Obeticholic acid（OCA）
1.2.3 Selonsertib
1.2.4 Emricasan
1.2.5 GR-MD-02
1.2.6 IMM-124E
1.3 Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2016-2027)
2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Regions
2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Share by Regions (2016-2021)
2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2022-2027)
2.3 Nonalcoholic Steatohepatitis (NASH) Industry Dynamic
2.3.1 Nonalcoholic Steatohepatitis (NASH) Market Trends
2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2016-2021)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2016-2021)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2020
3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2016-2021)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2022-2027)

5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2016-2021)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
6.2.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
6.2.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
6.2.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
6.3.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
6.3.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
6.4.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
6.4.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
7.2.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
7.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
7.2.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application
7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
7.3.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
7.3.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
7.4.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
7.4.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type
8.2.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application
8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
8.4 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
8.4.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
9.2.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
9.2.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
9.2.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
9.3.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
9.3.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
9.3.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
9.4 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
9.4.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
9.4.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type
10.2.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application
10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
10.4 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
10.4.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Tobira Therapeutics
11.1.1 Tobira Therapeutics Company Details
11.1.2 Tobira Therapeutics Business Overview
11.1.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
11.1.4 Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.1.5 Tobira Therapeutics Recent Development
11.2 Cadila Healthcare
11.2.1 Cadila Healthcare Company Details
11.2.2 Cadila Healthcare Business Overview
11.2.3 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Introduction
11.2.4 Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.2.5 Cadila Healthcare Recent Development
11.3 Conatus Pharmaceuticals
11.3.1 Conatus Pharmaceuticals Company Details
11.3.2 Conatus Pharmaceuticals Business Overview
11.3.3 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.3.4 Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.3.5 Conatus Pharmaceuticals Recent Development
11.4 Galmed Pharmaceuticals
11.4.1 Galmed Pharmaceuticals Company Details
11.4.2 Galmed Pharmaceuticals Business Overview
11.4.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.4.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.4.5 Galmed Pharmaceuticals Recent Development
11.5 Gemphire Therapeutics
11.5.1 Gemphire Therapeutics Company Details
11.5.2 Gemphire Therapeutics Business Overview
11.5.3 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
11.5.4 Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.5.5 Gemphire Therapeutics Recent Development
11.6 Genfit
11.6.1 Genfit Company Details
11.6.2 Genfit Business Overview
11.6.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
11.6.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.6.5 Genfit Recent Development
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Details
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Introduction
11.7.4 Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.7.5 Gilead Sciences Recent Development
11.8 Intercept Pharmaceuticals
11.8.1 Intercept Pharmaceuticals Company Details
11.8.2 Intercept Pharmaceuticals Business Overview
11.8.3 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.8.4 Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.8.5 Intercept Pharmaceuticals Recent Development
11.9 Novartis International
11.9.1 Novartis International Company Details
11.9.2 Novartis International Business Overview
11.9.3 Novartis International Nonalcoholic Steatohepatitis (NASH) Introduction
11.9.4 Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.9.5 Novartis International Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Nonalcoholic Steatohepatitis (NASH) Introduction
11.10.4 Takeda Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
11.10.5 Takeda Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Obeticholic acid（OCA）
Table 3. Key Players of Selonsertib
Table 4. Key Players of Emricasan
Table 5. Key Players of GR-MD-02
Table 6. Key Players of IMM-124E
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2016-2021)
Table 11. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2022-2027)
Table 13. Nonalcoholic Steatohepatitis (NASH) Market Trends
Table 14. Nonalcoholic Steatohepatitis (NASH) Market Drivers
Table 15. Nonalcoholic Steatohepatitis (NASH) Market Challenges
Table 16. Nonalcoholic Steatohepatitis (NASH) Market Restraints
Table 17. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players (2016-2021)
Table 19. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2020)
Table 20. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
Table 24. Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2016-2021)
Table 28. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2016-2021)
Table 32. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million)
Table 64. Tobira Therapeutics Company Details
Table 65. Tobira Therapeutics Business Overview
Table 66. Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
Table 67. Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 68. Tobira Therapeutics Recent Development
Table 69. Cadila Healthcare Company Details
Table 70. Cadila Healthcare Business Overview
Table 71. Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Product
Table 72. Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 73. Cadila Healthcare Recent Development
Table 74. Conatus Pharmaceuticals Company Details
Table 75. Conatus Pharmaceuticals Business Overview
Table 76. Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 77. Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 78. Conatus Pharmaceuticals Recent Development
Table 79. Galmed Pharmaceuticals Company Details
Table 80. Galmed Pharmaceuticals Business Overview
Table 81. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 82. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 83. Galmed Pharmaceuticals Recent Development
Table 84. Gemphire Therapeutics Company Details
Table 85. Gemphire Therapeutics Business Overview
Table 86. Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
Table 87. Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 88. Gemphire Therapeutics Recent Development
Table 89. Genfit Company Details
Table 90. Genfit Business Overview
Table 91. Genfit Nonalcoholic Steatohepatitis (NASH) Product
Table 92. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 93. Genfit Recent Development
Table 94. Gilead Sciences Company Details
Table 95. Gilead Sciences Business Overview
Table 96. Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Product
Table 97. Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 98. Gilead Sciences Recent Development
Table 99. Intercept Pharmaceuticals Company Details
Table 100. Intercept Pharmaceuticals Business Overview
Table 101. Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 102. Intercept Pharmaceuticals Recent Development
Table 103. Novartis International Company Details
Table 104. Novartis International Business Overview
Table 105. Novartis International Nonalcoholic Steatohepatitis (NASH) Product
Table 106. Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 107. Novartis International Recent Development
Table 108. Takeda Company Details
Table 109. Takeda Business Overview
Table 110. Takeda Nonalcoholic Steatohepatitis (NASH) Product
Table 111. Takeda Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
Table 112. Takeda Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2020 VS 2027
Figure 2. Obeticholic acid（OCA） Features
Figure 3. Selonsertib Features
Figure 4. Emricasan Features
Figure 5. GR-MD-02 Features
Figure 6. IMM-124E Features
Figure 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Online Provider Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions: 2020 VS 2027
Figure 15. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2022-2027)
Figure 16. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2020
Figure 17. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2020
Figure 19. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2016-2021)
Figure 20. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2022-2027)
Figure 21. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
Figure 23. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
Figure 24. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
Figure 25. United States Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
Figure 29. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
Figure 30. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
Figure 31. Germany Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2016-2027)
Figure 41. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
Figure 49. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
Figure 50. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
Figure 51. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
Figure 57. Turkey Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Tobira Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 61. Cadila Healthcare Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 62. Conatus Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 63. Galmed Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 64. Gemphire Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 65. Genfit Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 66. Gilead Sciences Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 67. Intercept Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 68. Novartis International Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 69. Takeda Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---